Maio M, et al. - In the BRIM8 study, adjuvant vemurafenib monotherapy was evaluated in adults (≥18 years age) with histologically confirmed stage IIC–IIIA–IIIB (cohort 1) or stage IIIC (cohort 2) BRAF^V600 mutation-positive fully resected melanoma. In cohort 2, the primary endpoint of disease-free survival was not met, and hence the analysis of cohort 1 demonstrating a numerical benefit in disease-free survival with vemurafenib vs placebo in patients with resected stage IIC–IIIA–IIIB BRAF^V600 mutation-positive melanoma must be considered exploratory only. Good tolerability of adjuvant vemurafenib was demonstrated; however, it might not be an optimal treatment regimen in this patient population.